Alumis Inc. Files 8-K with Exhibits

Ticker: ALMS · Form: 8-K · Filed: Mar 30, 2026 · CIK: 0001847367

Alumis Inc. 8-K Filing Summary
FieldDetail
CompanyAlumis Inc. (ALMS)
Form Type8-K
Filed DateMar 30, 2026
Risk Levellow
Pages4
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, exhibits

TL;DR

Alumis filed an 8-K on 3/30/26 - check exhibits for details.

AI Summary

Alumis Inc. filed an 8-K on March 30, 2026, reporting other events and financial statements. The filing includes various exhibits, such as graphics, indicating potential updates or disclosures related to the company's operations or financial performance.

Why It Matters

This 8-K filing by Alumis Inc. may contain important updates or disclosures that could affect investor understanding of the company's current status and future prospects.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant negative events.

Key Numbers

  • 2026-03-30 — Filing Date (Date Alumis Inc. filed the 8-K report.)
  • 2026-03-28 — Period of Report (The reporting period covered by the 8-K filing.)

Key Players & Entities

  • Alumis Inc. (company) — Filer of the 8-K report
  • 0001847367 (company) — CUSIP number for Alumis Inc.
  • 0001104659-26-036386 (filing_id) — SEC Accession Number for the 8-K filing

FAQ

What specific 'Other Events' are detailed in Item 8.01 of the filing?

The provided text does not specify the content of Item 8.01, only that it is an 'Other Events' section.

What is the nature of the financial statements and exhibits mentioned in Item 9.01?

The filing lists numerous graphic exhibits (e.g., .jpg files) and document types (e.g., iXBRL 8-K, EX-99.1, EX-99.2), suggesting financial or operational data is presented visually or in detailed exhibits.

Are there any significant financial figures or dollar amounts disclosed in the exhibits?

The provided text lists file sizes for exhibits but does not detail the content or specific financial figures within them.

What is the purpose of the numerous graphic exhibits attached to this 8-K filing?

The graphic exhibits likely serve to visually present data, such as charts, graphs, or diagrams, related to Alumis Inc.'s business or financial performance, as indicated by their file names and types.

Does this filing indicate any material changes in Alumis Inc.'s business operations or financial condition?

The filing is an 8-K reporting 'Other Events' and financial statements/exhibits, which *could* indicate material changes, but the specific nature of these changes is not detailed in the provided summary text.

Filing Stats: 1,060 words · 4 min read · ~4 pages · Grade level 15.3 · Accepted 2026-03-30 06:06:35

Key Financial Figures

  • $0.0001 — e on which registered Common Stock, $0.0001 par value per share ALMS The Nasdaq

Filing Documents

01 Other Events

Item 8.01 Other Events. On March 28, 2026, Alumis Inc. (the "Company" or "Alumis") issued a press release titled "Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis". The Company is also filing slides presented by the Company at a late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting on March 28, 2026. Copies of the press release and presentation are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K (the "Report") and are incorporated by reference. The information contained in the presentation is summary information that is intended to be considered in the context of the more complete information included in the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in the presentation in this Report, although it may do so from time to time as its management believes is appropriate. Any such update may be made through the filing of other reports or documents with the SEC.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking an NDA in the second half of 2026, the potential for envudeucitinib to transform the treatment landscape for IL-23/IL-17-driven diseases as well as those driven by Type I interferon, the potential for envudeucitinib to meaningfully elevate care for and effectively reduce the full burden of disease for patients with moderate-to-severe plaque psoriasis, the expected availability of one-year Phase 3 long-term data in the second half of 2026, the development of a once-daily formulation and a pediatric development plan for envudeucitinib, the ongoing nature of the ONWARD clinical program, the timing of Alumis' topline readout in its LUMUS Phase 2b program and statements regarding Alumis' future plans and prospects, including development of its clinical pipeline; and any assumptions underlying any of the foregoing, are forward-looking statements. Any forward-looking statements in this Report are based on Alumis' current expectations, estimates and projections only as of the date of this Report and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results, levels of activity, safety, efficacy, performance or events and circumsta

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 99.1 Press Release, dated March 28, 2026. 99.2 Late-Breaker Presentation, dated March 28, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alumis Inc. By: /s/ Martin Babler Martin Babler President & Chief Executive Officer Dated: March 30, 2026

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.